Diphenoxylate / Atropine to Decrease FDG Activity During F-18 FDG PET
Status:
Completed
Trial end date:
2005-09-01
Target enrollment:
Participant gender:
Summary
2-[18F]-fluoro-2-deoxyD-glucose positron emission tomography (FDG PET) has proven to be a
valuable clinical tool for the staging and surveillance of lymphoma.1-6 Occasionally, lymph
nodes in the mesentery and retroperitoneum can be difficult to distinguish from normal bowel
activity on PET scans despite three-plane and cine maximal image projection (MIP) imaging.
This uncertainty limits the clinical usefulness of PET in some cases of lymphoma.7-8 In
addition, bowel activity can also hinder interpretation of PET scans in other types of solid
tumors including melanoma and colorectal cancer.6,9,10 Our goal is to determine how well
diphenoxylate/atropine 5mg/0.05mg (Lomotil) decreases bowel activity and how this decrease
impacts clinical decision-making, specifically for lymphoma staging and surveillance. This is
a prospective, randomized, double-blinded study involving 60 patients undergoing PET scans
for newly diagnosed or recurrent, untreated lymphoma.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Atropine Atropine sulfate-diphenoxylate hydrochloride drug combination Diphenoxylate